Marketing Approval, Quarterly Reports, and Donation - Research Report on Allergan, Forest, Cubist, Sanofi, and The Medicines

   Marketing Approval, Quarterly Reports, and Donation - Research Report on
         Allergan, Forest, Cubist, Sanofi, and The Medicines Company

PR Newswire

NEW YORK, November 1, 2013

NEW YORK, November 1, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Allergan
Inc. (NYSE: AGN), Forest Laboratories Inc. (NYSE: FRX), Cubist Pharmaceuticals
Inc. (NASDAQ: CBST), Sanofi (NYSE: SNY), and The Medicines Company (NASDAQ:
MDCO). Today's readers may access these reports free of charge - including
full price targets, industry analysis and analyst ratings - via the links
below.

Allergan Inc. Research Report

On October 23, 2013, Allergan Inc. (Allergan) announced that the US Food and
Drug Administration has given its approval to market JUVÉDERM VOLUMA XC, the
first and only filler approved to temporarily correct age-related volume loss
in the cheek area in adults over the age of 21. Scott M. Whitcup, M.D.,
Executive Vice President, Research and Development, Chief Scientific Officer,
Allergan, stated, "We are pleased that the FDA has now approved JUVÉDERM
VOLUMA XC, the first product of its kind specifically formulated to correct
age-related volume loss in the cheek area. JUVÉDERM VOLUMA XC represents the
latest innovation in Allergan's growing portfolio of facial aesthetic products
developed to address previously unmet patient needs." The Full Research Report
on Allergan Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/182a_AGN]

Forest Laboratories Inc. Research Report

On October 22, 2013, Forest Laboratories Inc. (Forest) released its Q2 FY 2014
results (period ended September 30, 2013). Forest registered net revenues of
$855.3 million in Q2 FY 2014, up 12.4% YoY. The Company posted net income of
$70.0 million in Q2 FY 2014, up 236.8% YoY. Forest reported diluted EPS of
$0.26, up compared to $0.08 in Q2 FY 2013. Commenting on the results, Brent
Saunders, CEO and President of Forest, said, "There is rejuvenation underway
at Forest as we return to growth. We have a motivated and talented workforce,
we are launching new products and we are developing new drugs to drive future
growth. This quarter sales increased 17% and non-GAAP earnings per share more
than doubled." Saunders continued, "To make Forest more relevant to all of our
key stakeholders - customers & patients; owners; partners and colleagues - we
are conducting a thorough review of our business operations and evaluating
changes to our strategy." The Full Research Report on Forest Laboratories Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/ea24_FRX]

Cubist Pharmaceuticals Inc. Research Report

On October 22, 2013, Cubist Pharmaceuticals Inc. (Cubist) released its Q3 2013
results. Cubist registered total net revenues of $266.0 million in Q3 2013, up
11.7% YoY. The Company posted net loss of $33.9 million in Q3 2013, compared
to net income of $40.3 million in Q3 2012. Cubist further reported diluted
loss per share of $0.50 in Q3 2013, compared to diluted EPS of $0.55 in Q3
2012. Michael Bonney, CEO of Cubist, stated, "This was an exciting quarter for
Cubist as we extended our global leadership in the acute care environment and
took a major step towards achieving our Building Blocks of Growth strategic
goals. We believe our transactions to acquire Trius and Optimer will enhance
our product portfolio and position us to further leverage our differentiated
business model with our promising pipeline candidates." Bonney added, "We look
forward to another important quarter ahead that we expect will include
top-line data readouts from the cUTI and cIAI trials of our Phase 3 candidate
ceftolozane/tazobactam." The Full Research Report on Cubist Pharmaceuticals
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/92f2_CBST]

Sanofi Research Report

On October 21, 2013, Sanofireported that it has signed agreements to donate €2
million to support the first two academic chairs of the new French-German
Centre Virchow-Villermé for Public Health, in commemoration of the 50th
anniversary of the Elysée Treaty. Christopher A. Viehbacher, CEO of Sanofi,
commented, "In the 50th year of the Elysée Treaty, the donation of these first
two Chairs further supports the intensive collaboration between our two
countries in the field of science, politics and the economy." Viehbacher
concluded, "It is only through partnership that we can succeed and through
these chairs, we are bringing together actors in education, research, science
and industry to make a real difference in promoting health and well-being."
The Full Research Report on Sanofi - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.AnalystsCorner.com/r/full_research_report/29ea_SNY]

The Medicines Company Research Report

On October 23, 2013, The Medicines Company released its Q3 2013 results. The
Medicines Company registered net revenue of $174.3 million in Q3 2013, up
27.4% YoY. Net income attributable to the Company was $7.8 million in Q3 2013,
compared to $9.3 million in Q3 2012. The Company reported diluted EPS of $0.12
in Q3 2013, compared to diluted EPS of $0.17 in Q3 2012. Glenn Sblendorio,
President and Chief Financial Officer of The Medicines Company, stated, "The
third quarter was yet another financial growth period and we made significant
progress with our acute/intensive care portfolio." Sblendorio continued, "We
continue to make progress on our late stage development programs with four
product launches anticipated in the next 12 to 24 months. We are serving a
concentrated, yet growing worldwide hospital market while leveraging and
building our organization efficiently, consistent with our purpose to save
lives, alleviate suffering, and contribute to the economics of healthcare by
focusing on leading hospitals worldwide." The Full Research Report on The
Medicines Company - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/5a84_MDCO]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Media Contact: Joe Thomas, +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.